Even One Ventures
Even One Ventures is a San Francisco-based biotech venture builder founded by Sid Sijbrandij that creates portfolio companies developing individualized treatments for patients who have exhausted conventional options across oncology, immune, women's health, and rare disease.
- Company typePrivate
- Founded2025
- HeadquartersSan Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Even One Ventures does
Even One Ventures is a San Francisco-based biotech venture builder founded in 2024-2025 by Sid Sijbrandij. The firm originates from Sijbrandij's personal experience navigating recurrent osteosarcoma after exhausting conventional treatment options: he assembled a team, pursued diagnostics, and ran individualized treatments in parallel. Even One Ventures was created to productize that patient-driven playbook by building biotech companies focused on rapidly making scientific advances accessible to patients who have run out of standard therapeutic options. The stated therapeutic focus spans four verticals — Oncology, Immune, Women's Health, and Rare Disease.
The underlying model is company creation rather than traditional fund investing. Even One Ventures builds portfolio biotech companies that develop individualized treatments and operate diagnostic and therapeutic programs in parallel for patients with high-unmet-need conditions. No specific pipeline assets, clinical-stage programs, or product launches are disclosed in the available material, and the portfolio appears to be in early formation. Distribution of any eventual treatments is intended to reach patients and healthcare providers globally through the portfolio companies.
The business model is venture-capital returns through equity ownership in the biotech companies the firm builds. There is no disclosed product pricing, management fee structure, fund close, or external investor base; the firm appears founder-led and independently operated. With 1-10 employees and no disclosed funding rounds, partnerships, or revenue, the company is at an earliest-stage operating posture, with awareness built primarily through founder networks, healthcare communities, and founder storytelling (including coverage in Century of Bio and on sytse.com).
Even One Ventures firmographics
Firmographics- Name
- Even One Ventures
- Website
- https://evenone.ventures
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Even One Ventures is a San Francisco-based biotech venture builder founded by Sid Sijbrandij that creates portfolio companies developing individualized treatments for patients who have exhausted conventional options across oncology, immune, women's health, and rare disease.
- Ownership category
- akta.pro rank
Even One Ventures industry classification
Industry- Product category
- Biotech Venture Capital
- NAICS
- Funds, Trusts, and Other Financial Vehicles (525), Other Financial Vehicles (52599)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Venture Studios / Company Builders (FSANAAAH)
Keywords
Where Even One Ventures is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Markets served
Even One Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D
Revenue model
- Venture Capital Returns: Even One Ventures generates returns through equity ownership in portfolio biotech companies that it builds and supports. The company was inspired by founder Sid Sijbrandij who built individualized treatments for his own cancer, demonstrating the potential for patient-driven biotech innovation.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Even One Ventures product offering
Product offeringCore offering
Even One Ventures is a biotech venture builder that starts and supports early-stage healthcare and life sciences companies focused on making scientific advances rapidly accessible to patients. The firm operates across Oncology, Immune, Women's Health, and Rare Disease, building companies that pursue diagnostics and run individualized therapeutic programs in parallel for patients who have exhausted conventional treatment options.
Product overview
Even One Ventures is a biotech venture capital firm that builds and invests in biotech companies focused on making scientific advances accessible to patients. The firm operates across four therapeutic focus areas: Oncology, Immune, Women's Health, and Rare Disease. The company's portfolio consists of portfolio companies rather than traditional product offerings.
Differentiator
Problem solved
Functional benefit
Products and services
- Biotech Venture Building Services
- Individualized Treatment Playbook
Companies that use Even One Ventures
Customer profileSegments1 record
Ideal customer profiles2 records
Even One Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Even One Ventures partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights4 records
Even One Ventures competitors and assessment
Company assessmentBroad incumbents
- Andreessen Horowitz (a16z Bio): Andreessen Horowitz's bio fund invests across the biotech and healthtech stack with a much larger platform and broader mandate. While it does not operate as a venture builder, it competes for the same founder talent and therapeutic-area opportunities as Even One Ventures.
- Khosla Ventures: Khosla Ventures is a large venture firm with a meaningful biotech and healthcare practice that invests across stages. It is a broader incumbent versus Even One Ventures' specialized builder focus, but overlaps in early-stage science-driven investing.
- GV (Google Ventures): GV invests across sectors including life sciences and biotech with a brand-driven, founder-friendly platform. It is a broader incumbent compared to Even One Ventures, but overlaps in backing high-conviction biotech founders at the earliest stages.
Direct peers
- ARCH Venture Partners: ARCH Venture Partners invests early in deep-tech and biotech companies, often co-founding or seeding them. Its long-duration, science-heavy thesis and willingness to build companies from scratch make it a comparable peer for Even One Ventures.
- Flagship Pioneering: Flagship Pioneering is the archetypal biotech venture builder, originating and growing companies (e.g., Moderna) around novel scientific platforms. Even One Ventures applies the same build-rather-than-buy model but focused specifically on individualized therapeutics for high-unmet-need indications, making Flagship the closest structural analog.
- Foresite Capital: Foresite Capital is a healthcare and biotech-focused investment firm that backs early-stage companies across therapeutics and tools. Its concentrated healthcare thesis and willingness to form companies around novel science make it a comparable peer.
- Versant Ventures: Versant Ventures is a healthcare-focused venture firm that both invests in and builds biotech companies across therapeutic areas. Its mix of de novo company creation and traditional investing aligns closely with Even One Ventures' builder-plus-investor positioning.
- OrbiMed: OrbiMed is a dedicated healthcare investment firm operating across the biotech, medtech, and diagnostics spectrum with substantial AUM. Even One Ventures competes for similar early-stage biotech opportunities, particularly in oncology and rare disease.
- Section 32: Section 32 is a biotech-focused venture fund founded by Bill Maris (former GV head) that invests across multiple therapeutic areas at early stages. Its thesis of identifying frontier biotech opportunities and supporting them through company formation is structurally similar to Even One Ventures' approach.
- Atlas Venture: Atlas Venture is an early-stage biotech VC that builds and seeds new companies around emerging science, with a focus on rare diseases and platform technologies. Its builder-like approach to forming companies makes it a direct peer to Even One Ventures' model.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Even One Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Even One Ventures leadership team
Management profileNumber of profiles
Profiles1 record
Even One Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Even One Ventures M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Even One Ventures
What does Even One Ventures do?
Even One Ventures is a biotech venture builder that starts and supports early-stage healthcare and life sciences companies focused on making scientific advances rapidly accessible to patients. The firm operates across Oncology, Immune, Women's Health, and Rare Disease, building companies that pursue diagnostics and run individualized therapeutic programs in parallel for patients who have exhausted conventional treatment options.
Is Even One Ventures a public or private company?
Even One Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Even One Ventures founded?
Even One Ventures was founded in 2025. It employs 1 to 10 people.
Where is Even One Ventures based?
Even One Ventures is headquartered in San Francisco, United States, in the North America region.
How does Even One Ventures make money?
One revenue line is on record: venture Capital Returns.
Who are Even One Ventures's main competitors?
Broad incumbents on record are Andreessen Horowitz (a16z Bio), Khosla Ventures and GV (Google Ventures). Direct peers are ARCH Venture Partners, Flagship Pioneering, Foresite Capital, Versant Ventures, OrbiMed, Section 32 and Atlas Venture.
Does Even One Ventures have an API?
No public API is recorded for Even One Ventures.
What industry is Even One Ventures in?
Even One Ventures's product category is Biotech Venture Capital. Its primary akta.pro industry code is FSANAAAH, Venture Studios / Company Builders. Its NAICS code is 525 and its SIC code is 6282.